The Deal Landscape At Mid-Year: Is Industry Following Through On Business Development Promises?
Pfizer/Biohaven Is Only $10bn-Plus M&A In First Half
Executive Summary
INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022.
You may also be interested in...
Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
Merck Reports Good News/Bad News In Latest Keytruda Readouts
With successful Phase III data, Merck will look to add biliary tract cancer to Keytruda’s label, but it will discontinue a Phase III study in prostate cancer after an interim analysis showed no survival benefit.